2024
Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records
Doran W, Tunnicliffe L, Muzambi R, Rentsch C, Bhaskaran K, Smeeth L, Brayne C, Williams D, Chaturvedi N, Eastwood S, Dunachie S, Mathur R, Warren-Gash C. Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records. BMJ Open Diabetes Research & Care 2024, 12: e003548. PMID: 38272537, PMCID: PMC10823924, DOI: 10.1136/bmjdrc-2023-003548.Peer-Reviewed Original ResearchConceptsRisk of dementiaMild cognitive impairmentOral glucose-lowering therapyDementia riskObservational cohort studyAs-treated analysisGlucose-lowering therapyRisk of incident all-cause dementiaUK adultsCompare risk of dementiaIncident all-cause dementiaType 2 diabetesClinical Practice Research DatalinkActive comparator new user designCohort studyAll-cause dementiaPrimary healthcare recordsIncident dementia riskAssociated with lower riskPotential exposure misclassificationCox proportional hazards regressionMetformin useRisk of confoundingProportional hazards regressionIncident dementiaHypertension Control During the Coronavirus Disease 2019 Pandemic
Korves C, Peixoto A, Lucas B, Davies L, Weinberger D, Rentsch C, Vashi A, Young-Xu Y, King J, Asch S, Justice A. Hypertension Control During the Coronavirus Disease 2019 Pandemic. Medical Care 2024, 62: 196-204. PMID: 38284412, PMCID: PMC10922611, DOI: 10.1097/mlr.0000000000001971.Peer-Reviewed Original ResearchConceptsHypertension controlFollow-up intervalPrimary care clinic visitsFollow-up lengthVeterans Health AdministrationControlled hypertensionUncontrolled hypertensionGeneralized estimating equationsCohort of individualsStudy inclusion criteriaHealth careHealth AdministrationLonger follow-up intervalsBlood pressure measurementsAssessed associationsClinic visitsInclusion criteriaDecreased likelihoodEstimating equationsPrepandemic periodLow likelihoodCoronavirus diseaseFollow-upHypertensionIndividualsHerpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study
Tunnicliffe L, Weil R, Breuer J, Rodriguez‐Barradas M, Smeeth L, Rentsch C, Warren‐Gash C. Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study. Movement Disorders 2024, 39: 438-444. PMID: 38226430, PMCID: PMC10922272, DOI: 10.1002/mds.29701.Peer-Reviewed Original ResearchConceptsUS Department of Veterans AffairsCohort studyRisk of incident PDDepartment of Veterans AffairsCox proportional hazards regressionIncident Parkinson's diseaseAssociated with increased riskHistory of HZMatched cohort studyProportional hazards regressionRisk of PDHerpes zosterIncident PDRisk of incident Parkinson's diseaseVeterans AffairsIncident HZUS veteransPD overallHazards regressionPD riskParkinson's diseaseIncreased riskMatched individualsUS DepartmentAssociated with Parkinson's disease
2023
Excess mortality in US Veterans during the COVID-19 pandemic: an individual-level cohort study
Weinberger D, Bhaskaran K, Korves C, Lucas B, Columbo J, Vashi A, Davies L, Justice A, Rentsch C. Excess mortality in US Veterans during the COVID-19 pandemic: an individual-level cohort study. International Journal Of Epidemiology 2023, 52: 1725-1734. PMID: 37802889, PMCID: PMC10749763, DOI: 10.1093/ije/dyad136.Peer-Reviewed Original ResearchConceptsExcess mortality ratesExcess mortalityComorbidity burdenHazard ratioCohort studyMortality rateVeterans Aging Cohort Study (VACS) IndexIndividual-level cohort studyVeterans AffairsCOVID-19 pandemicLarge integrated healthcare systemExcess mortality patternsHigher comorbidity burdenLower comorbidity burdenMost frail patientsCharlson Comorbidity IndexObservational cohort studyClinical risk groupsIntegrated healthcare systemLeast frailComorbidity indexFrail patientsPre-pandemic periodMedian ageUS veteransAlcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
Cartwright E, Pierret C, Minassian C, Esserman D, Tate J, Goetz M, Bhattacharya D, Fiellin D, Justice A, Re V, Rentsch C. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy. JAMA Network Open 2023, 6: e2335715. PMID: 37751206, PMCID: PMC10523171, DOI: 10.1001/jamanetworkopen.2023.35715.Peer-Reviewed Original ResearchConceptsSustained virologic responseAlcohol use disorderHigh-risk consumptionHistory of AUDLow-risk consumptionDAA therapyAlcohol use categoriesAlcohol useVirologic responseCohort studyAntiviral therapyOdds ratioChronic hepatitis C virus (HCV) infectionAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionVeterans AffairsActing antiviral (DAA) therapyDAA treatment initiationHCV elimination goalsUndetectable HCV RNAC virus infectionFibrosis-4 scoreRetrospective cohort studyMultivariable logistic regressionTenth Revision diagnosisContribution of alcohol use in HIV/hepatitis C virus co‐infection to all‐cause and cause‐specific mortality: A collaboration of cohort studies
Trickey A, Ingle S, Boyd A, Gill M, Grabar S, Jarrin I, Obel N, Touloumi G, Zangerle R, Rauch A, Rentsch C, Satre D, Silverberg M, Bonnet F, Guest J, Burkholder G, Crane H, Teira R, Berenguer J, Wyen C, Abgrall S, Hessamfar M, Reiss P, Monforte A, McGinnis K, Sterne J, Wittkop L, Collaboration T. Contribution of alcohol use in HIV/hepatitis C virus co‐infection to all‐cause and cause‐specific mortality: A collaboration of cohort studies. Journal Of Viral Hepatitis 2023, 30: 775-786. PMID: 37338017, PMCID: PMC10526649, DOI: 10.1111/jvh.13863.Peer-Reviewed Original ResearchConceptsHepatitis C virusAntiretroviral therapyAlcohol useC virusHIV/hepatitis C virusHeavy drinkersMultivariable Cox modelModerate alcohol drinkersNorth American cohortCause-specific mortalityGrams/dayBaseline alcohol useSelf-reported alcohol useHigher alcohol useART initiationHCV statusCohort studyHazard ratioAdult PWHAlcohol drinkersAlcohol use dataCox modelPWHAmerican cohortMortalityExcess Mortality Among Patients in the Veterans Affairs Health System Compared With the Overall US Population During the First Year of the COVID-19 Pandemic
Weinberger D, Rose L, Rentsch C, Asch S, Columbo J, King J, Korves C, Lucas B, Taub C, Young-Xu Y, Vashi A, Davies L, Justice A. Excess Mortality Among Patients in the Veterans Affairs Health System Compared With the Overall US Population During the First Year of the COVID-19 Pandemic. JAMA Network Open 2023, 6: e2312140. PMID: 37155169, PMCID: PMC10167568, DOI: 10.1001/jamanetworkopen.2023.12140.Peer-Reviewed Original ResearchConceptsGeneral US populationVA health care systemHealth care systemComprehensive medical careOverall US populationRate of deathVA populationUS populationDeath rateCohort studyExcess mortalityCare systemCOVID-19 pandemicMedical careVeterans Affairs Health Care SystemVeterans Affairs Health SystemHealth systemVA health systemFirst yearVA health careStandardized mortality rateAdult age groupsVA enrolleesMAIN OUTCOMEGeneral populationEnhanced Identification of Hispanic Ethnicity Using Clinical Data
Ochoa-Allemant P, Tate J, Williams E, Gordon K, Marconi V, Bensley K, Rentsch C, Wang K, Taddei T, Justice A, Cohorts F. Enhanced Identification of Hispanic Ethnicity Using Clinical Data. Medical Care 2023, 61: 200-205. PMID: 36893404, PMCID: PMC10114212, DOI: 10.1097/mlr.0000000000001824.Peer-Reviewed Original ResearchConceptsBurden of diseaseHispanic patientsCountry of birthClinical dataHispanic ethnicityNon-Hispanic white patientsSex-adjusted prevalenceChronic liver diseaseHuman immunodeficiency virusDemographic characteristicsElectronic health record dataHealth careHealth record dataPrevalence of conditionsUS health care systemMedicare administrative dataHealth care systemWhite patientsLiver diseaseImmunodeficiency virusSelf-reported ethnicityHigh prevalenceGastric cancerHepatocellular carcinomaVeteran population
2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchMeSH KeywordsAlcoholismAntiviral AgentsCohort StudiesHepacivirusHepatitis CHepatitis C, ChronicHumansMaleMiddle AgedConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosisSpironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies
Farokhnia M, Rentsch CT, Chuong V, McGinn MA, Elvig SK, Douglass EA, Gonzalez LA, Sanfilippo JE, Marchette RCN, Tunstall BJ, Fiellin DA, Koob GF, Justice AC, Leggio L, Vendruscolo LF. Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Molecular Psychiatry 2022, 27: 4642-4652. PMID: 36123420, PMCID: PMC10231646, DOI: 10.1038/s41380-022-01736-y.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DrinkingAlcoholismAnimalsCohort StudiesEthanolFemaleHumansMaleMiceRatsRodentiaSpironolactoneConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-ConsumptionEffect of spironolactoneAlcohol consumptionSpironolactone doseNovel pharmacotherapiesUse disordersHuman studiesLarge integrated healthcare systemHeavy episodic alcohol consumptionAlcohol-induced ataxiaMineralocorticoid receptor antagonistsSelf-reported alcohol consumptionBlood alcohol levelsEpisodic alcohol consumptionIntegrated healthcare systemPharmacoepidemiologic cohort studyPotential new pharmacotherapiesCohort studyAlcohol drinkingReceptor antagonistFemale miceFemale ratsNew pharmacotherapiesRat modelAre infections associated with cognitive decline and neuroimaging outcomes? A historical cohort study using data from the UK Biobank study linked to electronic health records
Muzambi R, Bhaskaran K, Rentsch C, Smeeth L, Brayne C, Garfield V, Williams D, Chaturvedi N, Warren-Gash C. Are infections associated with cognitive decline and neuroimaging outcomes? A historical cohort study using data from the UK Biobank study linked to electronic health records. Translational Psychiatry 2022, 12: 385. PMID: 36109502, PMCID: PMC9478085, DOI: 10.1038/s41398-022-02145-z.Peer-Reviewed Original ResearchConceptsCognitive declineWhite matter hyperintensity volumeSecondary care recordsAssociation of infectionHistory of infectionPotential structural correlatesEvidence of associationCommon infectionsDementia riskHyperintensity volumeInfection diagnosisCare recordsCognitive impairmentLinear mixed effects modelsCognitive functionVolunteer cohortInfectionMixed effects modelsStructural correlatesUK BiobankLinear regression modelsAssociationEffects modelRegression modelsVisual memoryRecording of ’COVID-19 vaccine declined‘: a cohort study on 57.9 million National Health Service patients’ records in situ using OpenSAFELY, England, 8 December 2020 to 25 May 2021
Curtis HJ, Inglesby P, MacKenna B, Croker R, Hulme WJ, Rentsch CT, Bhaskaran K, Mathur R, Morton CE, Bacon SC, Smith RM, Evans D, Mehrkar A, Tomlinson L, Walker AJ, Bates C, Hickman G, Ward T, Morley J, Cockburn J, Davy S, Williamson EJ, Eggo RM, Parry J, Hester F, Harper S, O’Hanlon S, Eavis A, Jarvis R, Avramov D, Griffiths P, Fowles A, Parkes N, Evans SJ, Douglas IJ, Smeeth L, Goldacre B. Recording of ’COVID-19 vaccine declined‘: a cohort study on 57.9 million National Health Service patients’ records in situ using OpenSAFELY, England, 8 December 2020 to 25 May 2021. Eurosurveillance 2022, 27: 2100885. PMID: 35983770, PMCID: PMC9389857, DOI: 10.2807/1560-7917.es.2022.27.33.2100885.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesCOVID-19COVID-19 VaccinesEnglandHumansRetrospective StudiesState MedicineVaccinationConceptsCOVID-19 vaccinationCOVID-19 vaccineCohort studyPriority patientsRetrospective cohort studyPrimary care recordsMore deprived areasUnvaccinated patientsSubsequent vaccinationSouth Asian peopleSouth Asian populationGeneral practicePatientsCare recordsClinical record systemsVaccinationNHS EnglandPatient recordsVaccineDeprived areasAsian populationsOpenSAFELYDemographic subgroupsRecord systemDemographic factorsAssociation between household composition and severe COVID-19 outcomes in older people by ethnicity: an observational cohort study using the OpenSAFELY platform
Wing K, Grint DJ, Mathur R, Gibbs HP, Hickman G, Nightingale E, Schultze A, Forbes H, Nafilyan V, Bhaskaran K, Williamson E, House T, Pellis L, Herrett E, Gautam N, Curtis HJ, Rentsch CT, Wong AYS, MacKenna B, Mehrkar A, Bacon S, Douglas IJ, Evans SJW, Tomlinson L, Goldacre B, Eggo RM. Association between household composition and severe COVID-19 outcomes in older people by ethnicity: an observational cohort study using the OpenSAFELY platform. International Journal Of Epidemiology 2022, 51: 1745-1760. PMID: 35962974, PMCID: PMC9384728, DOI: 10.1093/ije/dyac158.Peer-Reviewed Original ResearchComparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY
Hulme WJ, Williamson EJ, Green ACA, Bhaskaran K, McDonald HI, Rentsch CT, Schultze A, Tazare J, Curtis HJ, Walker AJ, Tomlinson LA, Palmer T, Horne EMF, MacKenna B, Morton CE, Mehrkar A, Morley J, Fisher L, Bacon SCJ, Evans D, Inglesby P, Hickman G, Davy S, Ward T, Croker R, Eggo RM, Wong AYS, Mathur R, Wing K, Forbes H, Grint DJ, Douglas IJ, Evans SJW, Smeeth L, Bates C, Cockburn J, Parry J, Hester F, Harper S, Sterne JAC, Hernán MA, Goldacre B. Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY. The BMJ 2022, 378: e068946. PMID: 35858680, PMCID: PMC9295078, DOI: 10.1136/bmj-2021-068946.Peer-Reviewed Original ResearchMeSH KeywordsBNT162 VaccineCohort StudiesCOVID-19COVID-19 VaccinesHealth PersonnelHumansSARS-CoV-2Social SupportViral VaccinesConceptsCovid-19 related hospital admissionCOVID-19 vaccineCOVID-19 diseaseRelated hospital admissionsCumulative incidenceHospital admissionSocial care workersCare workersCohort studyHealthcare workersPositive SARS-CoV-2 testBNT162b2 COVID-19 vaccineChAdOx1 COVID-19 vaccineSARS-CoV-2 positive testSARS-CoV-2 infectionSARS-CoV-2 alpha variantSARS-CoV-2 testCOVID-19First vaccine doseComparative effectiveness trialFirst dose vaccinationBNT162b2 mRNAHospital attendanceVaccine doseVaccine typesTenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV
Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, Casas JP, Dickerman BA, Rentsch CT, Justice AC, Hernán MA. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 2022, 36: 1689-1696. PMID: 35848570, PMCID: PMC9444875, DOI: 10.1097/qad.0000000000003314.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCohort StudiesCOVID-19COVID-19 TestingEmtricitabineHIV InfectionsHumansLamivudineMaleSARS-CoV-2TenofovirConceptsTDF/FTCTenofovir disoproxil fumarateCoronavirus disease 2019 (COVID-19) outcomesTAF/FTCAntiretroviral therapyTenofovir alafenamideDisoproxil fumarateRisk ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCOVID-19 ICU admissionsIntensive care unit admissionPrevious COVID-19 diagnosisSyndrome coronavirus 2 infectionCOVID-19-related hospitalizationVeterans Aging Cohort StudySARS-CoV-2 infectionCare unit admissionCoronavirus 2 infectionChronic kidney diseaseHIV viral loadGlomerular filtration rateAging Cohort StudyCorresponding risk ratioPooled logistic regressionDescribing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY
Green A, Curtis H, Hulme W, Williamson E, McDonald H, Bhaskaran K, Rentsch C, Schultze A, MacKenna B, Mahalingasivam V, Tomlinson L, Walker A, Fisher L, Massey J, Andrews C, Hopcroft L, Morton C, Croker R, Morley J, Mehrkar A, Bacon S, Evans D, Inglesby P, Hickman G, Ward T, Davy S, Mathur R, Tazare J, Eggo R, Wing K, Wong A, Forbes H, Bates C, Cockburn J, Parry J, Hester F, Harper S, Douglas I, Evans S, Smeeth L, Goldacre B. Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY. BMC Medicine 2022, 20: 243. PMID: 35791013, PMCID: PMC9255436, DOI: 10.1186/s12916-022-02422-0.Peer-Reviewed Original ResearchMeSH KeywordsChickenpox VaccineCohort StudiesCOVID-19COVID-19 VaccinesEnglandHumansRetrospective StudiesSARS-CoV-2VaccinationConceptsPositive SARS-CoV-2 testSARS-CoV-2 testBreakthrough COVID-19Vaccine breakthroughBreakthrough casesCohort studyIncidence rateCOVID-19COVID-19-related hospital admissionsCOVID-19-related deathsVaccine breakthrough casesRetrospective cohort studyChronic kidney diseaseCritical care admissionSARS-CoV-2 variantsDeath registry dataCorresponding incidence ratesRoutine clinical dataHigh rateMedian followVaccine waningCare admissionHospital admissionSecond vaccinationSecondary careAssociations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study
Trickey A, Zhang L, Gill MJ, Bonnet F, Burkholder G, Castagna A, Cavassini M, Cichon P, Crane H, Domingo P, Grabar S, Guest J, Obel N, Psichogiou M, Rava M, Reiss P, Rentsch CT, Riera M, Schuettfort G, Silverberg MJ, Smith C, Stecher M, Sterling TR, Ingle SM, Sabin CA, Sterne JAC. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. The Lancet HIV 2022, 9: e404-e413. PMID: 35659335, PMCID: PMC9647005, DOI: 10.1016/s2352-3018(22)00046-7.Peer-Reviewed Original ResearchConceptsIntegrase strand inhibitorsCause mortalityCohort studyThird drugAntiretroviral drugsMortality rateAntiretroviral Therapy Cohort CollaborationFirst-line ART regimensUK Collaborative HIV CohortART-naive peopleCollaborative HIV CohortAntiretroviral therapy regimensUK Medical Research CouncilMedical Research CouncilCohort CollaborationEfavirenz regimensVirological benefitVirological failureVirological suppressionART regimensHIV cohortHazard ratioRoutine careTherapy regimensUS National InstitutesAssociation between oral anticoagulants and COVID-19 related outcomes: a population-based cohort study
Wong AY, Tomlinson L, Brown JP, Elson W, Walker AJ, Schultze A, Morton CE, Evans D, Inglesby P, MacKenna B, Bhaskaran K, Rentsch CT, Powell E, Williamson E, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Cockburn J, McDonald HI, Mathur R, Wing K, Forbes H, Eggo RM, Evans SJ, Smeeth L, Goldacre B, Douglas IJ, . Association between oral anticoagulants and COVID-19 related outcomes: a population-based cohort study. British Journal Of General Practice 2022, 72: bjgp.2021.0689. PMID: 35440465, PMCID: PMC9037187, DOI: 10.3399/bjgp.2021.0689.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticoagulantsAtrial FibrillationCohort StudiesCOVID-19HumansSARS-CoV-2StrokeConceptsCOVID-19 outcomesPopulation-based cohort studySevere COVID-19 outcomesSARS-CoV-2Oral anticoagulantsLower riskVASc scoreCohort studyHazard ratioAtrial fibrillationCOVID-19 related outcomesCOVID-19-related deathsPrescribed oral anticoagulantsPrimary care dataBaseline stroke riskOAC useCurrent useStroke riskHospital admissionThrombotic eventsCox regressionOAC usersReduced infection riskGeneral practiceDeath records
2021
HIV care using differentiated service delivery during the COVID‐19 pandemic: a nationwide cohort study in the US Department of Veterans Affairs
McGinnis KA, Skanderson M, Justice AC, Akgün KM, Tate JP, King JT, Rentsch CT, Marconi VC, Hsieh E, Ruser C, Kidwai‐Khan F, Yousefzadeh R, Erdos J, Park LS. HIV care using differentiated service delivery during the COVID‐19 pandemic: a nationwide cohort study in the US Department of Veterans Affairs. Journal Of The International AIDS Society 2021, 24: e25810. PMID: 34713585, PMCID: PMC8554215, DOI: 10.1002/jia2.25810.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesCOVID-19FemaleHIV InfectionsHumansMalePandemicsSARS-CoV-2United StatesVeteransConceptsVeterans AffairsClinic visitsCohort studyVL testARV coverageCOVID-19 pandemicVeterans Aging Cohort StudyHIV healthcare deliveryNationwide cohort studyAging Cohort StudyViral load testsDifferentiated service deliveryHealthcare deliveryHIV careMost patientsPharmacy recordsVL testingCalendar periodHealthcare encountersOverall healthARVVirtual healthcareVirtual visitsVisitsService deliveryAssociation between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study
Wong A, Tomlinson L, Brown J, Elson W, Walker A, Schultze A, Morton C, Evans D, Inglesby P, MacKenna B, Bhaskaran K, Rentsch C, Powell E, Williamson E, Croker R, Bacon S, Hulme W, Bates C, Curtis H, Mehrkar A, Cockburn J, McDonald H, Mathur R, Wing K, Forbes H, Eggo R, Evans S, Smeeth L, Goldacre B, Douglas I. Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study. Journal Of Hematology & Oncology 2021, 14: 172. PMID: 34666811, PMCID: PMC8525065, DOI: 10.1186/s13045-021-01185-0.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPopulation-based cohort studyCOVID-19-related outcomesSevere COVID-19Oral anticoagulantsCohort studyHazard ratioLower riskNegative control outcome analysisSevere COVID-19 diseaseNon-valvular atrial fibrillationPrimary care dataCOVID-19 outcomesCOVID-19COVID-19 diseaseNegative control outcomesDOAC usersOpenSAFELY platformWarfarin usersHospital admissionAtrial fibrillationClinical evidenceCox regressionResultsA totalOutcome analysis